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We examined whether personality disorders (PDs) (any, cluster A/B/C) were associated
with bone mineral density (BMD) in a population-based sample of Australian women
(n = 696). Personality and mood disorders were assessed using semi-structured
diagnostic interviews. BMD was measured at the spine, hip, and total body using
dual-energy x-ray absorptiometry (GE-Lunar Prodigy). Anthropometrics, medication use,
physical conditions, and lifestyle factors were documented. The association between
PDs (any, cluster A/B/C) and BMD (spine/hip/total body) was examined with multiple
linear regression models. The best models were identified by backward elimination
including age, weight, physical activity, smoking status, alcohol consumption, dietary
calcium intake, mood disorders, physical multimorbidity, socioeconomic status, and
medications affecting bone. The variables were retained in the model if p < 0.05. All
potential interactions in final models were tested. Those with cluster A PD, compared
to those without, had 6.7% lower hip BMD [age, weight adjusted mean 0.853 (95%
CI 0.803–0.903) vs. 0.910 (95% CI 0.901–0.919) g/cm2, p = 0.027] and 3.4% lower
total body BMD [age, weight, smoking, alcohol, calcium adjusted mean 1.102 (95% CI
1.064–1.140) vs. 1.139 (95% CI 1.128–1.150) g/cm2, p = 0.056]. No associations were
observed between cluster B/C PDs and hip/total body BMD or between any of the PD
clusters and spine BMD. To our knowledge, this study is the first to investigate the bone
health of women with PD in a population-based sample. Given the paucity of literature,
replication and longitudinal research including the examination of underlying mechanisms
and sex differences are warranted.
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INTRODUCTION
Emerging early in the life span, a personality disorder (PD)
presents as enduring patterns of maladaptive thinking,
emotional and inner experiences, and behaviors—causing
significant distress and impairment (1). PDs have traditionally
been conceptualized as 10 distinct disorders that are
organized within three clusters: A, “odd-eccentric” features; B,
“dramatic/emotional/erratic” features; and C, “anxious/fearful”
features (1).
Growing evidence points to adverse physical health
comorbidities among people with PD, including chronic
physical, pain, and sleep conditions (2, 3)—however, little is
known regarding the factors underlying these associations (2).
PD also appears to be associated with musculoskeletal problems
(2, 3); however, there is a paucity of research examining the
underlying bone health of people with PD.
Psychological/behavioral factors including impulsivity and
self-sabotaging type behaviors, which are typical of “cluster
B” symptomatology, appear to lead to difficulties with general
health treatment compliance (4) and thus plausibly influence
the physical health of people with these PDs. Biological/other
health-related factors are suggested to include (but may not
be limited to) multiple and long-term poor health-related
lifestyle choices and medication use (5, 6) and metabolic
syndrome (3). However, little is known whether different PD
clusters (i.e., different presentations of PD symptomatology) are
independently associated with poorer bone health compared to
people without PDs.
Kahl et al. (7, 8) conducted the first clinical-based studies
showing that comorbid borderline PD (a cluster B PD) and
depressive disorders were associated with reduced bone mineral
density (BMD) in younger women. Yet, there are no studies
from the population-based setting or across the wider adult
age range. Therefore, we explored direct associations between
PD and BMD in a large population-based sample of Australian
women—exploring the role of age, anthropometrics, lifestyle
factors, multimorbidity, medication use, and mood disorders.
MATERIALS AND METHODS
This study examined data from women participating in
the population-based Geelong Osteoporosis Study (GOS) in
Australia (9). Originally, 1,494 women (response rate 77.1%)
were randomly selected from the electoral rolls for the Barwon
Statistical Division during 1994–1996. Complete details have
been published elsewhere (9–11). We utilized data collected from
participants who returned for assessment during 2011–2014.
Participants who did not complete a psychiatric assessment (n
= 80), had missing BMD data (n = 50), or with multiple PD
Abbreviations: BMD, bone mineral density; CI, confidence interval; DSM,
Diagnostic and Statistical Manual of Mental Disorders; IRSAD, Index of Relative
Socio-economic Advantage and Disadvantage; MDD, major depressive disorder;
PD, personality disorder; SCID-I/NP, The Structured Clinical Interview for
Diagnostic and Statistical Manual of Mental Disorders Axis I Disorders, non-
patient edition; SCID-II, The Structured Clinical Interview for DSM-IV Axis II
personality disorders; SES, socioeconomic status.
clusters (n = 22) were excluded. This study consisted of n = 696
women aged ≥28 years. Barwon Health Human Research Ethics
Committee approved the study, and written informed consent
was obtained from all participants.
Areal BMD (g/cm2) was measured at the posterior–
anterior (PA) spine (L2–4), femoral neck (hip), and total
body including head using dual-energy X-ray absorptiometry
(Prodigy; GE Lunar, Madison, WI, USA). Technicians carried
out all examinations and performed daily calibrations of the
densitometer with equipment-specific phantoms. Osteoporosis
was determined by a BMD T-score of <-2.5 at the spine
and/or hip (12).
The Structured Clinical Interview for Diagnostic and
Statistical Manual of Mental Disorders (DSM) Axis I Disorders,
non-patient edition (SCID-I/NP) identified lifetime mood
disorders [i.e., major depressive disorder (MDD), minor
depression, bipolar disorder, dysthymia, mood disorders due
to a general medical condition, and substance-induced mood
disorder] (13). The Structured Clinical Interview for DSM-
IV Axis II personality disorders (SCID-II) identified PDs (14).
Consistent with the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5), the 10 PDs were categorized into three
clusters: cluster A PDs (i.e., schizoid, paranoid, and schizotypal
PDs); cluster B PDs (i.e., antisocial, borderline, narcissistic, and
histrionic PDs); and cluster C PDs (i.e., avoidant, dependent,
and obsessive–compulsive PDs) (1). As previously published,
all interviews were conducted by trained personnel with post-
graduate qualifications in psychology (10).
Weight and height were measured to the nearest 0.1 kg or
0.1 cm, respectively. Current smoking and mobility were self-
reported. Participants were deemed active if vigorous or light
exercise was performed regularly; otherwise, participants were
classified as sedentary. Alcohol consumption and calcium intake
were estimated from a validated food frequency questionnaire
(15). Current medication use affecting bone was recorded,
including antiresorptive agents (bisphosphonates/selective
estrogen receptor modulators), oral hormone replacement
therapy, oral glucocorticoids, and antidepressants. Participants
brought lists of medications or containers to the assessment
to ensure accurate recordings. Participants self-reported
the presence of physical conditions. These were confirmed
by medical record, medication use, or clinical data, where
possible, and included arthritis, cardiovascular disease,
thyroid disorders, metabolic disorders, gastrointestinal disease,
gastroesophageal reflux disease, syncope and seizures, recurrent
headaches, pulmonary diseases, psoriasis, liver diseases,
and cancers (16). Utilizing these data, we defined physical
multimorbidity as the presence of ≥5 lifetime physical health
disorders (17, 18). Area-based socioeconomic status (SES)
was determined using the Index of Relative Socio-economic
Advantage and Disadvantage (IRSAD). A lower score (Quintile
1) indicated greater disadvantage; a higher score, greater
advantage (Quintile 5) (9).
Statistical analyses were performed using Minitab (version
18). Group differences were determined using t-tests for
parametric variables, Kruskal–Wallis for nonparametric
continuous variables—for discrete variables, chi-square tests
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TABLE 1 | Characteristics of all and those with and without a PD.
All PD No PD p*
n = 696 n = 131 n = 565
Age (years) 56.2 (42.6–67.6) 52.2 (38.7–63.8) 57.1 (43.3–68.8) 0.012
Weight (kg) 71.5 (62.2–83.8) 77.0 (65.6–87.9) 70.1 (61.9–82.6) 0.003
Height (m) 1.62 ± 0.06 1.63 ± 0.07 1.62 ± 0.06 0.274
Smoking (current) 78 (11.4%) 18 (14.1%) 60 (10.8%) 0.291
Mobility (active) 507 (74.2%) 83 (65.4%) 424 (76.3%) 0.011
Alcohol intake (g/day) 2.2 (0.3–11.9) 1.8 (0.4–7.8) 2.4 (0.3–13.1) 0.527
Calcium intake (mg/day) 824 (637–1,037) 821 (597–1,089) 826 (640–1,032) 0.901
Mood disorder (lifetime) 255 (36.6%) 78 (59.4%) 177 (31.3%) <0.001
Physical multimorbidity (lifetime) 115 (16.5%) 29 (22.1%) 86 (15.2%) 0.055
Socioeconomic status 0.637
Quintile 1 (lowest) 103 (14.8%) 23 (17.6%) 80 (14.2%)
Quintile 2 76 (10.9%) 16 (12.2%) 60 (10.6%)
Quintile 3 269 (38.7%) 46 (35.1%) 223 (39.5%)
Quintile 4 135 (19.4%) 28 (21.4%) 107 (18.9%)
Quintile 5 113 (16.2%) 18 (13.7%) 95 (16.8%)
Medication use (current)
Antiresorptive agents 21 (3.0%) 3 (2.3%) 18 (3.2%) 0.589
Glucocorticoids 20 (2.9%) 4 (3.1%) 16 (2.8%) 0.778
Hormone therapy 26 (3.7%) 3 (2.3%) 23 (4.1%) 0.333
Antidepressants 114 (16.4%) 32 (24.4%) 82 (14.5%) 0.006
Unadjusted BMD (g/cm2)
Spine 1.20 ± 0.18 1.22 ± 0.18 1.20 ± 0.18 0.306
Hip 0.92 ± 0.14 0.94 ± 0.14 0.92 ± 0.14 0.048
Total body 1.14 ± 0.11 1.16 ± 0.11 1.13 ± 0.11 0.055
Osteoporosis (current) 57 (8.2%) 8 (6.1%) 49 (8.7%) 0.335
Values are given as median (interquartile range), mean ± standard deviation or n (%).
*Comparing women with and without PD.
BMD, bone mineral density; PD, personality disorder.
or Fisher’s exact test when expected cell counts were less than
five. The association between PD (any, cluster A/B/C) and
BMD (spine/hip/total body) was examined with multiple linear
regression in unadjusted models (Model I) and “best models”
(Model II). The best models were identified by backward
elimination including age, weight, physical activity, smoking
status, alcohol consumption, dietary calcium intake, mood
disorders, physical multimorbidity, SES, and medications
affecting bone (c.f. above). The variables were retained in the
model if p < 0.05. All potential interactions in final models
were tested.
RESULTS
Of 696 women, 131 (18.8%) met the criteria for a PD. Women
with PD were more likely to be younger, heavier, sedentary, use
antidepressants, had a lifetime mood disorder, and had higher
hip and total body BMD than those without PD (all p < 0.05);
otherwise, the groups were similar (Table 1).
After age, weight adjustments, no differences were detected in
spine, hip, or total body BMD between those with and without
any PD (all p > 0.05).
The frequency of PD clusters was: 2.7%, cluster A (n = 19);
<1%, cluster B (n= 5); and 15.4%, cluster C (n= 107).
Unadjusted and best models showing associations between
PD clusters and BMD are presented in Table 2. Those with
cluster A PD, compared to those without, had 6.7% lower hip
BMD [age, weight adjusted mean 0.853 (95% CI 0.803–0.903)
vs. 0.910 (95% CI 0.901–0.919) g/cm2, p = 0.027] and 3.4%
lower total body BMD [age, weight, smoking, alcohol, calcium
adjusted mean 1.102 (95% CI 1.064–1.140) vs. 1.139 (95% CI
1.128–1.150) g/cm2, p = 0.056]. No differences were detected in
spine BMDbetween those with and without cluster A PD. Finally,
no differences were detected in spine, hip, and total body BMD
for those with and without cluster B or C PDs.
DISCUSSION
To our knowledge, this study is the first to investigate bone health
of women with PD in a population-based sample. It showed that
those with cluster A PD have lower hip/total body BMD than
those without. There were no associations between pooled PDs,
cluster B or cluster C PD and BMD at any site.
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TABLE 2 | Unadjusted and best models presenting associations between PD clusters and BMD using multiple regression.
BMD site PD status Model I: unadjusted Model II: best model*
B SE p B SE p
Spine Cluster A 0.034 0.043 0.435 −0.010 0.039b 0.789
Cluster B 0.026 0.083 0.756 −0.025 0.083b 0.761
Cluster C 0.013 0.019 0.499 −0.005 0.018b 0.769
Hip Cluster A −0.007 0.033 0.834 −0.057 0.026a 0.027
Cluster B 0.006 0.064 0.922 −0.023 0.050a 0.645
Cluster C 0.034 0.015 0.027 0.009 0.012a 0.428
Total body Cluster A 0.009 0.025 0.724 −0.037 0.019c 0.056
Cluster B −0.021 0.049 0.675 −0.052 0.041d 0.202
Cluster C 0.023 0.011 0.045 0.005 0.009e 0.599
*Best models, adjusted for aage and weight; bage, weight, and alcohol; cage, weight, smoking, alcohol, and calcium intake; dage, weight, smoking, and alcohol; eage, weight, activity,
and smoking.
B, regression coefficient; BMD, bone mineral density; SE, standard error; PD, personality disorder.
Kahl et al. (7, 8) suggested that young women with borderline
PD and current major depression may be a group at risk of
developing osteoporosis. In their clinical study, the BMD of 24
women with MDD, 16 with borderline PD, 23 with MDD and
comorbid borderline PD, and 20 healthy control participants
were compared (7). The MDD only group were further divided
into younger/older age groups [mean age 30 years (MDD30); 43
years (MDD43), respectively]. Women with MDD and comorbid
borderline PD had significantly lower BMD at the lumbar
spine compared with women with borderline PD alone and
the younger women with MDD (MDD30) (7). No significant
associations were reported between the groups at the other
sites (i.e., right and left femur and forearm of non-dominant
hand) (7). Markers of bone turnover were also measured,
and compared with healthy control participants, elevated levels
of osteocalcin were reported among women with MDD and
borderline PD group (7). However, C-terminal degradation
products of type I collagen (CTx) were highest among the
MDD43 group, and tumor necrosis factor-α, interleukin-6, and
osteoprotegerin were highest among the MDD30 group (7). To
summarize, they postulated that rather than the presence of
borderline PD alone, the acuteness of a co-occurring MDD may
contribute to bone loss through associated immune/endocrine
disturbances (7, 8). Though not directly comparable, we
detected no direct association between cluster B and BMD.
However, the lack of associations between cluster B PD and
BMD detected in the present study could also be due to
power constraints.
The novelty of the current research precludes meaningful
comparisons with other studies on cluster A/C in relation to bone
health. It is possible that psychological/social factors/processes
that are characteristic of cluster A PDs, including enduring
social isolation and avoidance coping, may be a barrier
to engaging with healthcare providers for preventative,
ongoing monitoring of physical health and/or engagement
with treatments (2, 19)—including bone health. It is also
plausible that vitamin D intake could be a biological mechanism
underlying the associations.
In terms of study limitations, power limitations prevented
analyses investigating specific PDs, other psychiatric disorders,
and underlying biological mechanisms. Specifically, we did
not collect and, therefore, did not examine the role of
vitamin D, which is a known regulator of bone and mineral
metabolism, as a confounder/moderator of associations between
PD and BMD. This may be an area that warrants further
research, given the suggestion that vitamin D may play a
role in the manifestation of reduced quality of life via poorer
health status among postmenopausal women referred for
evaluation for osteopenia/osteoporosis (20) and, separately, with
poorer psychological and somatic symptomatology (21). We
also acknowledge that the classification of PD is undergoing
significant reform, and dimensional measures of personality were
not examined. Strengths of this study include the wide adult age
range, gold standard tool for assessing psychiatric disorders, and
adjustment for many known confounders.
Our preliminary study supports an association between
PD and bone health. A more substantive evidence base
is needed to further uncover the clinical implications of
a relationship between PD and bone health. It may be
important to determine whether monitoring the bone health
of people with PD and comorbidities is warranted, given
polypharmacotherapy is often prescribed for the treatment of
PD (22), and specific agents, such as selective serotonin reuptake
inhibitors, anticonvulsants, and antipsychotics, are associated
with decreased bone mass and increased risk for osteoporosis
and related fractures (23). This may require a coordinated effort
between primary and endocrinological care, given indications
that psychological/behavioral symptoms of PD may be a barrier
to general health treatment/compliance for some individuals (4).
Given the paucity of literature, replication and longitudinal
research including the examination of underlying mechanisms
and sex differences are warranted.
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